Tissue Regenix, NHS Blood and Transplant deal
Tissue Regenix amended a deal with NHS Blood and Transport (NHSBT) in order to expand the scope of clinical development activities for Tissue Regenix's dCELL technology. Under the original deal, NHSBT has the right to conduct preclinical and clinical evaluation using the dCELL technology to develop and manufacture human tissue-derived clinical products for use by the NHS. The expansion includes the development of decellularized human dermis and products for cardiology. Tissue Regenix said NHSBT's "development capacity and clinical network" will allow the company to fast track the clinical evaluation of additional human tissue applications for the technology. Tissue Regenix has the exclusive commercialization rights to all data generated from NHSBT trials. Details were not disclosed. ...